Bayer has submitted a novel MRI contrast agent named Gadoquatrane to the FDA for review. This agent is designed to address concerns associated with gadolinium, a rare earth metal used in current contrast agents that can have negative health and environmental impacts. Gadoquatrane is being evaluated for use in contrast-enhanced MRI scans of the central nervous system and other body regions in both adult and pediatric patients, including newborns. The product has also been submitted for approval in the EU and is under review in Japan.
One of the key advantages of Gadoquatrane is its significantly reduced gadolinium content compared to existing gadolinium-based contrast agents (GBCAs). If approved, it would become the lowest dose macrocyclic GBCA available in the US, with a 60% reduction in gadolinium levels. While gadolinium is generally deemed safe for MRI use, it can pose risks for individuals with kidney dysfunction, potentially leading to serious conditions like nephrogenic systemic fibrosis (NSF). Moreover, concerns have been raised about gadolinium persistence in the body and its potential toxic effects, even in individuals with healthy kidneys.
Studies have also shown evidence of gadolinium contamination in various water sources globally, necessitating efforts to minimize its usage. The development of Gadoquatrane aligns with the increasing need for medical imaging due to rising rates of chronic diseases like cancer, neurological disorders such as multiple sclerosis, and cardiovascular conditions. Dr. Konstanze Diefenbach, Bayer’s head of radiology R&D, highlighted the benefits of reduced contrast media dosage, particularly for patients requiring multiple imaging procedures throughout their lifetime.
In the US alone, an estimated 12-18 million contrast-enhanced MRI scans are performed annually, with a global projection of around 63 million scans in 2023. The contrast agent market’s value surpasses $2 billion each year, indicating substantial sales potential for Gadoquatrane if approved. Data from phase 3QUANTI studies conducted earlier this year demonstrated that Gadoquatrane is as safe and effective as established GBCAs with a lower gadolinium exposure, making it a promising candidate for improving MRI procedures.
Bayer’s radiology business, encompassing contrast agents, injection systems, and AI-based diagnostic tools, generated €2.1 billion in revenue last year, showcasing its rapid growth within the company. The introduction of Gadoquatrane aligns with Bayer’s commitment to innovation and sustainability in healthcare, addressing both patient safety concerns and environmental impacts associated with gadolinium usage in MRI procedures.
- Gadoquatrane offers a promising solution for reducing gadolinium exposure in MRI scans, potentially enhancing patient safety and environmental sustainability.
- The contrast agent market’s annual value exceeding $2 billion signifies significant commercial opportunities for Gadoquatrane if it receives regulatory approval.
- Bayer’s investment in innovative radiology solutions, including Gadoquatrane, reflects its commitment to advancing healthcare technologies that prioritize patient well-being and environmental stewardship.
- The development of Gadoquatrane underscores the convergence of technological advancements and regulatory requirements in the healthcare industry, emphasizing the importance of continuous innovation to address evolving medical needs and challenges.
Tags: clinical trials, biosimilars, cell therapy, cell therapies
Read more on pharmaphorum.com